Table 1 Baseline demographic and clinical characteristics

Gender

Male, n (%)

112 (37.7)

Female, n (%)

185 (62.3)

Age (years)

Mean (SD)

54.6 (9.4)

Education level

Without studies, n (%)

4 (1.3)

Primary education, n (%)

81 (27.3)

Secondary education, n (%)

107 (36.0)

Higher education, n (%)

105 (35.4)

Current familiar situation

Living alone (excluding caregiver, if it applies), n (%)

34 (11.4)

Living with a relative, n (%)

263 (88.6)

Time from MS diagnosis to the study visit (years)

Mean (SD)

19.1 (9.0)

Valid n

296

Time from SPMS diagnosis to the study visit (years)

Mean (SD)

5.9 (5.3)

EDSS score at MS diagnosis

Mean (SD)

2.0 (1.2)

Valid n

147

EDSS score at SPMS diagnosis

Mean (SD)

5.1 (1.1)

Valid n

296

EDSS score at the study visit

Mean (SD)

5.9 (0.8)

Valid n

147

EDSS score at the study visit (grouped). n (%)

EDSS: 0–2.5

-

EDSS: 3–4.5

35 (11.8)

EDSS: 5–5.5

37 (12.5)

EDSS: 6

99 (33.3)

EDSS: 6.5

126 (42.4)

Comorbidities at the study visit. n (%)

Metabolic

85 (28.6)

Cardiovascular

55 (18.5)

Musculoskeletal and soft tissues

44 (14.8)

Urinary

29 (9.8)

Neurological

23 (7.7)

Autoimmune

15 (5.1)

Respiratory

14 (4.7)

Gastrointestinal

12 (4.0)

Neoplasia

9 (3.0)

Infections

3 (1.0)

Prescribed DMT at the study visit. n (%)

Any DMT

170 (57.2)

Rituximab

72 (24.2)

Beta 1a-interferon

19 (6.4)

Fingolimod

18 (6.1)

Glatiramer acetate

15 (5.1)

Beta 1b-interferon

13 (4.4)

Dimethyl fumarate

8 (2.7)

Natalizumab

8 (2.7)

Teriflunomide

7 (2.4)

Azathioprine

3 (1.0)

Cladribine

3 (1.0)

Ocrelizumab

2 (0.7)

Beta 1a-interferon + azathioprine

1 (0.3)

Beta 1a-peginterferon

1 (0.3)